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tion. ConClusions: The dimensions excluding Ability of act all had the higher 
sensitivity on AIMS2-2F scale, which means overall sensitivity was better than 
SF-6D . Therefore, EQ-5D is more suitable for the evaluation of the QOL of patients 
with osteoarthritis. But the Psychological health dimension of SF-6D showed 
strong sensitivity, which prompts us Psychological problems are the important 
factors influencing the Osteoarthritis patients life quality.
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objeCtives: Biologic treatments have improved outcome for immunology diseases 
in the last decades globally. However, biologic penetration in China is lower com-
pared to developed countries. This study aims to explore the willingness-to-pay 
(WTP) for biologics in immunology diseases in China by understanding decisions 
driving physicians’ prescribing behavior and patients’ payment. Methods: Primary 
market research was done by interviewing 160 physicians with biologic experience, 
200 patients consisting of patients who have not received any biologic treatments 
before (bio-naïve), and patients with biologic experience (bio-experienced) from 
large hospitals (tier 3A) in Tier 1 and 2 cities. Patients were recruited with a diverse 
set of affordability as measured by household incomes. Results: The results show 
that patients rely on physicians for treatment recommendation. For rheumatoid 
arthritis, ankylosing spondylitis, and psoriasis, the top four factors driving physi-
cian’s recommendation are drug cost, patients’ ability-to-pay, safety of treatment 
and efficacy of treatment. For Ulcerative Colitis (UC) and Crohn’s Disease (CD), the 
top four factors were safety, efficacy, patients’ affordability followed by drug cost. 
The difference in pattern for UC and CD is likely attributed to the more severe 
nature of these diseases. Other factors such as injection frequency and mode of 
administration ranked lower for all indicators. ConClusions: Patients interview 
results show that ≈60% of bio-naïve patients were rejected biologic treatment due 
to cost; ≈30% of bio-experienced patients stopped biologic treatments due to cost. 
This confirms that affordability considerations do limit the potential benefit that 
biologic treatments can provide. Interestingly, ≈30% of bio-experienced patients 
have stopped biologic treatment as it was perceived that treatment course was 
completed. This could be attributed to how physicians perceive biologics to be used. 
While affordability limits biologic penetration in auto-immune diseases in China, 
there are other considerations e.g. the severity of diseases and physician perception 
of treatment paradigm.
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objeCtives: Use of innovative medicines in oncology and immunology is relatively 
lower in China compared to developed countries. This study aims to explore the 
willingness-to-pay (WTP) for these two therapeutic areas by understanding decisions 
driving physicians’ prescribing behavior and patients’ payment in immune diseases 
(rheumatoid arthritis, ankylosing spondylitis, and psoriasis) and oncology (prostate 
cancer). Methods: For immunology, primary market research was done by inter-
viewing 160 physicians with biologic experience, 200 patients consisting of patients 
who have not received any biologic treatments before (bio-naïve), and patients with 
biologic experience (bio-experienced). For oncology, 50 physicians and 40 patients 
were recruited. All physicians and patients were recruited from large hospitals (tier 
3A) from Tier 1, 2 cities. Patients were recruited to represent a diverse set of afford-
ability. Results: The results show that patients rely on physicians for treatment 
recommendation. For rheumatoid arthritis, ankylosing spondylitis, and psoriasis, the 
top four factors driving physician’s recommendation are drug cost, patients’ ability-
to-pay, safety of treatment and efficacy of treatment. For Ulcerative Colitis (UC) and 
Crohn’s Disease (CD), the top four factors were safety, efficacy, patients’ affordability 
followed by drug cost. The difference in pattern for UC and CD is likely attributed to 
the more severe nature of these diseases. Other factors such as injection frequency 
and mode of administration ranked lower for all indicators. For oncology, the top 
factors driving physician prescription are efficacy (overall survival, progression-free 
survival) followed by safety and tolerability. Patient affordability and drug cost are 
ranked much lower. Similarly, from patients interview results, efficacy was rated 
more important than cost as a factor driving willingness-to-pay. ConClusions: 
Observations from these two therapy areas show that cost and affordability are the 
top considerations when the diseases are less severe. For severe diseases and life-
threatening diseases, efficacy and safety of the drug are rated more than drug cost.
MuScular-SkElEtal DiSorDErS – health care use & Policy Studies
PMS28
StakEholDEr EviDEncE rEquirEMEntS anD PricE ExPEctationS for 
BioSiMilarS in thrEE aSian MarkEtS
Akpinar P.1, Saraf S.1, Severi Bruni D.2, Li X.3, Liu C.4, Sherwin G.1
1ICON Pricing and Market Access, London, UK, 2ICON Pricing and Market Access, San Francisco, 
CA, USA, 3ICON Commercialisation & Outcomes, London, UK, 4ICON Pricing and Market Access, 
New York, NY, USA
objeCtives: Between 2011 and 2015, 32 biologics valued at more than $55 bil-
lion are expected to lose patent protection across the world (Datamonitor 2011). 
The biologics patent cliff has presented a huge opportunity for biosimilar manu-
facturers. In the context of this growing biosimilars market, this research aimed 
to investigate the regulatory environments and the evidence (clinical, economic 
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objeCtives: To observe the clinical efficacy and economic value of Qin Xi-tong(QXT) 
during the long-term treatment for patients of RA. Methods: Caulis Sinomenii(CS) 
has been recognized as an effective medicinal plant for arthritis. The Fifth Hospital 
of Xi’an developed water extract from CS to a novel kind of drug naming QXT. RA was 
diagnosed in 200 patients referred to Department of Rheumatology. All the patients 
were classified according to their different areas. They were respectively evaluated 
by the score of VAS, DAS28 and the response rates of ACR20/70 .We also follow up 
the patients for the usage rate, treatment compliance and satisfaction of QXT. We 
count the cost of patients and the income of self-made chinese traditional medicine 
in our hospital to measure the economic value of QXT. Results: We found that: 1) 
There were 140 out of 200 patients who were from 14 provinces of China with RA 
using QXT.2. Percentage of the satisfaction and compliance with the treatment of 
QXT+MTX group were higher than MTX group, satisfaction rates (94.2% vs. 67.1%, 
X2= 11.7, P< 0.01) ,compliance rates (91.4% vs. 62.9%, X2= 16.2, P< 0.01) , respectively. 
3)statistical result of year 2 showed : Compared with pretherapy,QXT+ MTX group 
scored significantly lower of VAS, while achieving higher level of ACR20 and ACR70 . 
4)QXT was safe and well tolerated in this trial, difference of adverse events was not 
statistically significant. 5)The statistics showed the mean cost for QXT only occupied 
9.2%(78/856)of patient’s expenses for the treatment of RA. ConClusions: It is the 
first time to study the economic value of QXT in a randomized clinical trial for 2 
years. QXT+MTX could contribute to the higher clinical remission rates of patients 
with RA. It is worth noting that Chinese patients with RA was much better satisfied 
and complying with QXT which is actually consistent with our clinical practice.
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objeCtives: This study aims to identify the care needs for rheumatoid arthritis (RA) 
from patient perspectives. Methods: One-on-one in-depth interviews were con-
ducted with selected patients with RA in March 2014 in Singapore General Hospital 
as part of a larger ongoing study. The interviews were performed by a trained soci-
ologist following an interview guide allowing free probes. Each Interview lasted for 
20-60 minutes. 16 interviews were audio-recorded and transcribed with written 
consent from the patients. Notes were taken for the three unrecorded interviews. 
The transcripts and notes were analysed using NVivo 10 to identify major areas 
of patient-reported care needs. Results: 19 patients (11 Chinese, 2 Malays, and 6 
Indians; 17 females; age: 25-67 years; median educational level: higher secondary 
school) with 1-38 years of RA were interviewed. 15 had accepted that they would 
need lifelong RA medication; three were still testing if they could live without medi-
cation through self-experimentation; and one was in denial of the diagnosis. In 
additional to medical treatment, three other areas of care needs were identified: 
first, the need for knowledge about RA and its self-management (n= 17) ; second, 
the need for peer support to learn “how other people live with RA” (n= 11); and 
third, the need for psycho-emotional support to manage the emotional problems 
accompanying RA diagnosis (n= 9). These needs were most acute upon diagnosis 
and became less important once the patient had established new normality of life 
after having RA (e.g. avoiding things one cannot do due to RA without feeling bad, 
taking RA medication without feeling being hassled). ConClusions: The results 
of this study suggest that RA patients’ care needs are multidimensional and time 
sensitive. A muti-pronged approach including drug therapy, and patient education, 
support, and counselling is needed from start of treatment to help patients form 
the new normality of their lives.
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objeCtives: As the universal scales, EQ-5D and SF-6D have been widely used 
in the evaluation of the quality of life(QOL) of patients with many kinds of dis-
ease including Osteoarthritis. But as to which scale is much more suitable for the 
Osteoarthritis patients evaluation , there is scarcely any research so far. The cur-
rent study aimed to compare the correlation of the EQ -5D, SF-6D with AIMS2-2F 
scale, the specificity scale of QOL evaluation, then to determine the suitability of 
two scale for the QOL of patients with Osteoarthritis. Methods: From April to 
December in 2012, 100 patients with Osteoarthritis were enrolled with consent 
at Orthopedic Clinic in the First Affiliated Hospital of Chinese Medical University. 
They filled out the EQ-5D, SF-6D, and AIMS2 2F scales successively by themselves 
. SPSS19.0 analysis software was used to deal with the collected data, parts of the 
lack data were eliminated automatically . Cronbach alpha coefficient evaluated 
the internal consistency of scales. Pearson, Speaman and Kendall’s tau-b correla-
tion coefficient analysis were used to test the reliability between EQ-5D, SF-6D 
and AIMS2-2F score data. On the scale of the response and the factors affecting 
the QOL, we use multiple stepwise regression analysis, significant test of bilat-
eral boundary value point. Results: 77 sets of valid survey scale were analyst 
EQ-5D, SF-6D, and AIMS2-2F scales all had good internal consistency showing good 
reliability with the crowns Bach coefficient were all higher than 0.6.During the 
various dimensions of EQ-5D scale, Anxiety, Pain, Daily life and Self care showed 
the higher sensitivity on AIMS2-2F scale. Followed by Ability to act . As to SF-6D 
scale, Psychological health, Vitality, and Social function showed higher sensitiv-
ity on AIMS2-2F scale. And followed by Role constraints, Pain and Physical func-
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objeCtives: To investigate the mental health of rheumatic diseases patients and 
explore the effect of psychotherapy for the mental health status in rheumatism inpa-
tients. Methods: 1. To compare the mental health status in rheumatism inpatients 
with normal by SCL-90 score. 2. 66 inpatients with rheumatism were recruited in 
the study and randomly divided into study group (n= 33) and control group (n= 33). 
The patients in the study group accepted psychotherapy and pharmacotherapy, and 
control group only accepted pharmacotherapy. 3. Six weeks later, the effect of psycho-
therapy to rheumatism inpatients were assessed by comparing the score of SCL-90 
between the two groups. Results: 1. The SCL-90 score significantly increased in 
rheumatism inpatients group compared with normal group: rheumatism inpatients 
group (152.8±35.9) and normal group (129.9±38.7), (P< 0.05). 2. Six weeks later, the SCL-
90 sore of study group was lower than that of control group. 3. The SCL-90 score sig-
nificantly reduced after psychological treatment. ConClusions: The mental health 
status of rheumatism patients can not be ignored, because the patients have varying 
degrees of mental psychotic symptoms. The psychotherapy can improve the mental 
health status in rheumatism patients and can help the recovery of the patients.
rESPiratory-rElatED DiSorDErS – clinical outcomes Studies
PrS1
thE EffEctivEnESS anD SafEty of fEBuxoStat : an ExPEriEncE in 
MEDical cEntEr in taiWan
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objeCtives: The aim of this study was to assess the effectiveness and safety of 
febuxostat for chronic gout. Methods: We retrospectively review patients with 
diagnosis of gout (ICD-9 250) concomitant with febuxostat during Jun 2012 to Dec 
2013 in Changhua Christian Hospital. Patients with prescription of febuxostat less 
than 30 days were excluded. We collect the data of patient age, sex and analyzed the 
progression of renal function (eGFR) and uric acid. Prescribed Daily Dose (PDD) of 
febuxostat was calculated. Hospital-based spontaneous reporting systems databases 
were survey for the febuxostat adverse reaction reporting. Results: A total of 151 
patients were included with mean age 68.3±14.4 years. There were 40 female and 111 
male ( F:M ; 1:2.8).The average duration of prescription was 148.0±88.5 days. Prescribed 
Daily Dose (PDD) of febuxostat was 44mg. The uric acid was decrease from 9.1±1.9 to 
6.6±2.7mg/dL. The eGFR was increased from 33.5±23.5 to 34.9±25.1 ml/min/1.73m2. 
86.7% (131) of patients with eGFR < 60 ml/min/1.73m2 at the baseline. In subgroup 
analysis, 42 patients with the duration of prescription 31-90 days (average 55.8±15.6 
days ), 59 patients with 91-180 days(average 127.6±25.6 days), 50 patients with > 181 
days (average 249.6±68.77 days), the uric acid derement was 2.3±2.8 mg/dL, 2.6±2.9 
mg/dL and 2.8±2.1 mg/dL respectively. A total of 6 cases reported as mild adverse 
reaction, 4 cases reported as skin reaction. Other reactions reported was chills and 
insomnia.The incidence of ADR was 3.97%.(6/151). ConClusions: Febuxostat is an 
effective urate-lowering agent. We found a trend that the longer Febuxostat use, the 
more uric acid decline. The safety of febuxostat was well tolerated since the adverse 
reaction reported was mild. The total 6 cases adverse reaction reported were occurred 
in eGFR < 60 ml/min/1.73m2. Therefore, we need to closed monitor adverse reaction 
in CKD patients.
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objeCtives: Recent nested case-control studies have raised concerns of the risk for 
acute urinary retention (AUR) among patients receiving tiotropium, a long-acting 
inhaled anticholinergic. In this study, we examined the effect of inhaled anticho-
linergics on the occurrence of AUR using self-controlled methods, case-crossover 
and case-time-control designs, which adjust for all time-invariant confounders and 
reduce threat of control-selection bias. Methods: Patients aged ≥ 45 years with 
chronic obstructive pulmonary disease (COPD) were included from the IMS LifeLink 
Health Plan Claims Databases. Cases with AUR in both inpatient and outpatient set-
tings during 2006-2009 were identified. In the case-time-control approach, ten con-
trols were randomly selected for each case after matching age, gender, geographic 
location, to control for the secular trend of medication use. Exposure to tiotropium, 
ipratropium, and medications with significant anticholinergic effects was deter-
mined in the 30-day period prior to the event and in a 30-day reference period which 
was 180 days prior. Multivariate conditional logistic regression was used to evaluate 
the association between anticholinergic exposure and AUR, with sensitivity analyses 
and subgroup analyses based on age, gender and related comorbidities. Results: A 
total of 6,008 cases and 60,080 controls were identified. The mean age was 74 years 
and ~78% were male. In the case-crossover analysis, adjusted odds ratio (OR) of AUR 
was 1.34 (95%CI 1.13-1.60) for tiotropium and 1.19 (1.00-1.41) for ipratropium. In the 
case-time-control analysis, the risk of AUR OR was 1.24 (1.03-1.50) for tiotropium and 
1.26 (1.05-1.51) for ipratropium. The AUR risk related to tiotropium and ipratropium 
was similar among patients aged > 75 years, males, and those with benign prostate 
hyperplasia, prostate cancer, and diabetes. ConClusions: Our results support cur-
rent evidence that use of inhaled anticholinergics is associated with higher risk for 
AUR (odds increased by 20-35%) in COPD patients. Providers should be aware of the 
potential risk for AUR when making treatment decisions.
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and humanistic) requirements to support reimbursement and prescription of bio-
similar drugs in three Asian markets (Japan, South Korea and China). Methods: 
We conducted secondary research to review the macroeconomic factors impact-
ing biosimilar entry (regulatory policy, intellectual property protection etc.) Payer/ 
physician guidance and positions on biosimilar use across markets and diseases 
were also reviewed. Following this, primary research was conducted with a mix of 
payers and physician stakeholders to understand: 1. The therapy areas that payers/
physicians consider most attractive for biosimilars; 2. Payer/physician value drivers 
and evidence requirements (bioequivalence, comparative data etc.) across therapy 
areas that would support public reimbursement and prescription. 3. Expectations 
around price differentials vs. branded biologics and the implications these 
differentials have on access and utilization of biosimilars. Results: Evidence 
requirements vary by market, with Japan and S.Korea being fairly consistent while 
China having lower thresholds. Evidence requirements also tend to vary by therapy 
area and complexity of the biologic. Overall, efficacy/ safety data and price are key 
value drivers for biosimilar reimbursement and uptake. In the absence of com-
parative data vs. the branded biologic, concerns around safety/efficacy may impact 
uptake but the promise of significant budget savings supports positive reimburse-
ment/ access decisions. ConClusions: The access environments for biosimilars in 
the developed markets of Japan and S.Korea can be expected to be similar to other 
developed markets across the world. However, China is likely to be more favourable 
than the developed markets when it comes to access and uptake of biosimilars.
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objeCtives: Historically, there has been a delay between the marketing approval of 
drugs in Western countries and other markets worldwide. However, the pharmaceuti-
cal market in Asia is rapidly expanding (a projected increase in global market share of 
7% from 2000–2016). The objective of this analysis was to investigate patterns of drug 
approvals in Western and Asian countries. Methods: National English-language 
drug regulatory authority websites were searched for drug approval dates in key 
Western (United States and European Union) and Asian countries (Japan, Hong Kong, 
Indonesia and Singapore) in type 2 diabetes mellitus (T2DM) and rheumatoid arthritis 
(RA). For drugs with ≥ 1 approval in each region, we analysed how the delay in average 
approval date between the West and Asia changed over time. Results: At least 1 
West and 1 Asian approval was recorded for 21 drugs (T2DM n= 12, RA n= 9), out of the 
31 included. The delay between approval in the West and Asia was found to decrease 
between 2000 and 2014 in both T2DM and RA, and there was an overall strong negative 
correlation between the date of first approval and the delay (p< 0.0001; Spearman Rank 
correlation). Despite the delay for RA drugs (mainly biologics) being over double that 
of the T2DM (all small molecules) in 2000 (8.6 vs 3.6 years), by 2009 the delay for drugs 
in both indications was less than 2 years, due to a greater rate of decrease in delay for 
RA. ConClusions: Whilst the current analysis has limitations, it is clear that the 
delay in date of approval of T2DM and RA drugs in Western and APAC countries has 
decreased dramatically over the past decade. This may have an impact on the future 
marketing strategies of pharmaceutical companies. Further analysis would be needed 
to ascertain if this same trend is observed in other emerging markets.
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objeCtives: Every year, osteoporosis accounts for two million fragility fractures 
leading to disability, decreased quality of life and increased health care cost. Health 
literacy poses a challenge in delivering effective health care services. Impact of 
health literacy on health care utilization in the osteoporotic patients is unknown. 
We describe(1) health care utilization for osteoporosis patients in the USA(2) their pre-
scription drug expenses, and(3) examine any effects that health literacy may have on 
the above factors. Methods: This cross-sectional analysis used Medical Expenditure 
Panel Survey(MEPS) survey data from 2005 - 2008 and patients were identified using 
ICD-9 codes (733.xx) for osteoporosis. Patients’ health literacy levels(HLL) were 
determined by using the health literacy scores(HLS), rated using the 2003 National 
Assessment of Adult Literacy to levels from basic or below basic(BBHLL< 226) to above 
basic (ABHLL≥ 226) (range 0–500). The outcome variables were visits and costs as a 
function of HLL adjusted for other covariates. Adjusted logistic regression analyses 
determined factors that might influence HLL in osteoporotic patients. Results: 
Majority of the total of 915 (20,486,934 weighted) individuals (mean age, 67.4; SD±11.7) 
were women (92%), Caucasians (91%) and on bisphosphonates (78%). The estimated 
national mean of HLS was 220.3(SD±27.5). Average annual visits and visits expenditure 
were 13.9 and $1,587 respectively. Individuals with ABHLL incurred less annual visits 
(13.4 vs 14.3) but paid more per visit ($130vs.$103) compared to those with BBHLL. 
Self-perceived health status( SPHS) was rated 2.35 times greater by ABHLL than those 
with BBHLL (OR:2.352,CI:1.43,-3.87). Patients with polypharmacy(> 4 drugs) were 1.87 
times less likely to have ABHLL(P< 0.0001) than those with BBHLL. ConClusions: 
Osteoporosis patients with ABHLL incurred less annual visits but paid more per visit. 
While increasing HLL may not decrease visits or expenditure per visit, it may decrease 
drug expenses, polypharmacy and improve SPHS, all associated with better health 
care outcomes.
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